Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A single dose, randomised, 2-period, 2-sequence, crossover, comparative bioavailability study between R107 tablet and 60 mg ketamine IV solution administered orally in healthy male and female participants under fasting conditions.

Trial Profile

A single dose, randomised, 2-period, 2-sequence, crossover, comparative bioavailability study between R107 tablet and 60 mg ketamine IV solution administered orally in healthy male and female participants under fasting conditions.

Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 16 Oct 2018

At a glance

  • Drugs R 107 Radikal Therapeutics (Primary) ; Ketamine
  • Indications Major depressive disorder
  • Focus Pharmacokinetics
  • Most Recent Events

    • 11 Oct 2018 Status changed from not yet recruiting to withdrawn prior to enrolment.
    • 12 Jul 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top